These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 14616939)

  • 61. [Combined chemotherapy with molecular-targeted agent for breast cancer].
    Ito Y; Miura H
    Gan To Kagaku Ryoho; 2008 May; 35(5):731-6. PubMed ID: 18487908
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combination of trastuzumab and vinorelbine in metastatic breast cancer.
    Suzuki Y; Tokuda Y; Saito Y; Ohta M; Tajima T
    Jpn J Clin Oncol; 2003 Oct; 33(10):514-7. PubMed ID: 14623919
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
    Eniu A
    J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
    Rueckert S; Ruehl I; Kahlert S; Konecny G; Untch M
    Expert Opin Biol Ther; 2005 Jun; 5(6):853-66. PubMed ID: 15952915
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Therapy of breast cancer with molecular targeting agents.
    Gasparini G; Longo R; Torino F; Morabito A
    Ann Oncol; 2005 May; 16 Suppl 4():iv28-36. PubMed ID: 15923426
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Docetaxel in the treatment of breast cancer: an update on recent studies.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):28-34. PubMed ID: 12170449
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of Herceptin in primary breast cancer: views from North America and Europe.
    Leyland-Jones B; Smith I
    Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
    Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
    Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
    Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
    J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Herceptin in the adjuvant setting: phase III trials begin.
    McNeil C
    J Natl Cancer Inst; 2000 May; 92(9):683-4. PubMed ID: 10793100
    [No Abstract]   [Full Text] [Related]  

  • 73. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
    Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
    Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].
    Luo RC; Li AM; Zhang JY; Liao WJ; Ji CY; Miao JX
    Zhonghua Zhong Liu Za Zhi; 2004 Jan; 26(1):52-4. PubMed ID: 15059359
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Trastuzumab and breast cancer: developments and current status.
    Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
    [TBL] [Abstract][Full Text] [Related]  

  • 76. SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients.
    Altundag K; Mohamed AS; Altundag O; Silay YS; Gunduz E; Demircan K
    Med Hypotheses; 2005; 64(2):248-51. PubMed ID: 15607548
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Opinion on the use of the antitumor drug trastuzumab (Herceptin) in patients with metastatic breast cancer in the county Mecklenburg-Vorpommern.
    Hehl EM
    Int J Clin Pharmacol Ther; 2001 Nov; 39(11):503-6. PubMed ID: 11727972
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tolerability in patients receiving trastuzumab with or without chemotherapy.
    Gianni L
    Ann Oncol; 2001; 12 Suppl 1():S63-8. PubMed ID: 11521724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.